Press Releases

Date Title and Summary Additional Formats
Toggle Summary Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
INDIANAPOLIS , July 28, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Announces June Conference Presentations
Also Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
View HTML
Toggle Summary Assembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiome Gastrointestinal Development Programs to Allergan
INDIANAPOLIS , Feb. 21, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations
INDIANAPOLIS , Feb. 16, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the
View HTML
Toggle Summary Allergan Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development Programs
-- Expands Allergan's Innovative GI Pipeline with ABI-M201 and ABI-M301, Preclinical Compounds Targeting Ulcerative Colitis and Crohn's Disease, as well as Future Compounds for Irritable Bowel Syndrome -- DUBLIN, Ireland and INDIANAPOLIS , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN)
View HTML
Toggle Summary Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting
INDIANAPOLIS , Nov. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biotherapeutics for disorders associated with the
View HTML
Toggle Summary Assembly Biosciences Initiates Phase 1 Clinical Program of ABI-H0731 for Treatment of Chronic Hepatitis B Virus Infection
--First of Assembly's Novel Series of HBV Core Protein Allosteric Modulators Enters Clinical Development--
View HTML
Toggle Summary Assembly Biosciences Announces Key Additions to Microbiome Team
Assembly Adds Key Scientific, Manufacturing and Strategy Leadership to Support Its Expanding Microbiome Platform
View HTML
Toggle Summary Assembly Biosciences Announces Participation in HBV Scientific Meetings in China and South Korea
INDIANAPOLIS , Sept. 21, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics for disorders associated with the human
View HTML
Toggle Summary Assembly Biosciences to Present at the Jefferies 2016 Global Healthcare Conference
NEW YORK , June 01, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral biological therapeutics addressing disorders associated with the human
View HTML